KR102481704B1 - 항-인자 ix 파두아 항체 - Google Patents

항-인자 ix 파두아 항체 Download PDF

Info

Publication number
KR102481704B1
KR102481704B1 KR1020187036234A KR20187036234A KR102481704B1 KR 102481704 B1 KR102481704 B1 KR 102481704B1 KR 1020187036234 A KR1020187036234 A KR 1020187036234A KR 20187036234 A KR20187036234 A KR 20187036234A KR 102481704 B1 KR102481704 B1 KR 102481704B1
Authority
KR
South Korea
Prior art keywords
antibody
antigen
binding fragment
factor
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187036234A
Other languages
English (en)
Korean (ko)
Other versions
KR20190006548A (ko
Inventor
더크 보엘켈
로베르트 파흐링거
한스페터 로텐스타이너
알프레드 베버
안드레아 엔겔마이어
Original Assignee
다케다 파머수티컬 컴패니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59067875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102481704(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 다케다 파머수티컬 컴패니 리미티드 filed Critical 다케다 파머수티컬 컴패니 리미티드
Priority to KR1020227044875A priority Critical patent/KR102625416B1/ko
Publication of KR20190006548A publication Critical patent/KR20190006548A/ko
Application granted granted Critical
Publication of KR102481704B1 publication Critical patent/KR102481704B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/9645—Factor IX (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020187036234A 2016-05-16 2017-05-16 항-인자 ix 파두아 항체 Active KR102481704B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227044875A KR102625416B1 (ko) 2016-05-16 2017-05-16 항-인자 ix 파두아 항체

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662337118P 2016-05-16 2016-05-16
US62/337,118 2016-05-16
US201662340834P 2016-05-24 2016-05-24
US62/340,834 2016-05-24
PCT/US2017/032808 WO2017200981A1 (en) 2016-05-16 2017-05-16 Anti-factor ix padua antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227044875A Division KR102625416B1 (ko) 2016-05-16 2017-05-16 항-인자 ix 파두아 항체

Publications (2)

Publication Number Publication Date
KR20190006548A KR20190006548A (ko) 2019-01-18
KR102481704B1 true KR102481704B1 (ko) 2022-12-27

Family

ID=59067875

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187036234A Active KR102481704B1 (ko) 2016-05-16 2017-05-16 항-인자 ix 파두아 항체
KR1020227044875A Active KR102625416B1 (ko) 2016-05-16 2017-05-16 항-인자 ix 파두아 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227044875A Active KR102625416B1 (ko) 2016-05-16 2017-05-16 항-인자 ix 파두아 항체

Country Status (12)

Country Link
US (2) US11098132B2 (enExample)
EP (1) EP3458477B1 (enExample)
JP (3) JP7084878B2 (enExample)
KR (2) KR102481704B1 (enExample)
CN (1) CN109563154B (enExample)
AU (1) AU2017268198C1 (enExample)
BR (1) BR112018073660A2 (enExample)
CA (1) CA3024485A1 (enExample)
IL (1) IL262813B2 (enExample)
RU (2) RU2022108606A (enExample)
SG (1) SG11201809642TA (enExample)
WO (1) WO2017200981A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240007881A (ko) * 2022-07-08 2024-01-17 노보 노르디스크 에이/에스 FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CN110343181B (zh) * 2018-04-08 2022-04-08 苏州康宁杰瑞生物科技有限公司 针对凝血因子ix(fix)的单域抗体
WO2020128049A1 (en) 2018-12-21 2020-06-25 Kymab Limited Fixaxfx bispecific antibody with common light chain
GB202009928D0 (en) * 2020-06-29 2020-08-12 Freeline Therapeutics Ltd Method
CN118834275A (zh) * 2023-02-07 2024-10-25 湖南九典制药股份有限公司 一种抗菌/抗炎多肽及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
DK0826696T3 (da) 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
DE60219419T2 (de) 2001-01-19 2007-08-16 Ludwig Institute For Cancer Research Flt4 (vegfr-3) als ein ziel für krebsdarstellung und anti-krebs-behandlung
US20040096983A1 (en) * 2002-11-14 2004-05-20 Jacobs Merrit N. Wash process for a sample being analyzed
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
US20050282233A1 (en) 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
EP2824183B1 (en) * 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing bispecific antibodies
US8234784B2 (en) 2008-02-13 2012-08-07 Younger Steven W Valve piston repositioning apparatus and method
EP3542861A1 (en) * 2012-09-25 2019-09-25 Bioverativ Therapeutics Inc. Methods of using fix polypeptides
DK2911687T3 (da) * 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240007881A (ko) * 2022-07-08 2024-01-17 노보 노르디스크 에이/에스 FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물
KR102749341B1 (ko) 2022-07-08 2025-01-06 노보 노르디스크 에이/에스 FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물

Also Published As

Publication number Publication date
EP3458477B1 (en) 2025-07-09
IL262813B2 (en) 2025-12-01
JP2024056941A (ja) 2024-04-23
AU2017268198B2 (en) 2020-09-03
JP7084878B2 (ja) 2022-06-15
KR20230006026A (ko) 2023-01-10
AU2017268198A1 (en) 2018-11-22
RU2018138782A3 (enExample) 2020-07-14
IL262813B1 (en) 2025-08-01
AU2017268198C1 (en) 2020-11-26
KR102625416B1 (ko) 2024-01-15
JP2022133276A (ja) 2022-09-13
US20220056150A1 (en) 2022-02-24
SG11201809642TA (en) 2018-11-29
CN109563154A (zh) 2019-04-02
WO2017200981A1 (en) 2017-11-23
RU2770006C2 (ru) 2022-04-14
RU2018138782A (ru) 2020-06-17
CN109563154B (zh) 2024-12-13
JP7671887B2 (ja) 2025-05-02
KR20190006548A (ko) 2019-01-18
US11999798B2 (en) 2024-06-04
JP2019527033A (ja) 2019-09-26
RU2022108606A (ru) 2022-04-11
WO2017200981A8 (en) 2018-02-01
EP3458477A1 (en) 2019-03-27
NZ747752A (en) 2025-05-30
CA3024485A1 (en) 2017-11-23
IL262813A (en) 2018-12-31
BR112018073660A2 (pt) 2019-02-19
US20190194351A1 (en) 2019-06-27
US11098132B2 (en) 2021-08-24

Similar Documents

Publication Publication Date Title
US11999798B2 (en) Anti-factor IX padua antibodies
JP5753079B2 (ja) Ｈｅｒ２受容体またはその末端切断変異体を発現する癌を診断するための方法
WO2019184912A1 (zh) 抗cd47抗体及其用途
WO2019042285A1 (zh) 抗cd47抗体及其用途
US11814426B2 (en) Anti-tenascin C antibodies and uses thereof
CN103827144B (zh) 新的抗cxcr4抗体及其用于检测和诊断癌症的用途
RU2636032C2 (ru) Применение антитела i-3859 для выявления и диагностики рака
KR20220024211A (ko) 항-cd47 항체 및 그것의 사용
JP2016000713A (ja) 線維芽細胞増殖因子４に対するハイブリドーマクローンおよびモノクローナル抗体
JP2021532732A (ja) 糖タンパク質ｖｉを標的とする抗体
WO2019199896A1 (en) Agonist antibodies against human cd137 in cancer that express mhc i
HK40063373A (en) Anti-tenascin c antibodies and uses thereof
TW201311726A (zh) 抗體ｉ－３８５９用於癌症偵測及診斷之用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181213

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200512

Comment text: Request for Examination of Application

PN2301 Change of applicant

Patent event date: 20210917

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220321

Patent event code: PE09021S01D

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220922

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221222

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221222

End annual number: 3

Start annual number: 1

PG1601 Publication of registration